Singapore, October 20, 2022 – Update on Detection of the latest SARS-CoV-2 Variant Strain
In response to the emergence of new COVID-19 variants, and to mitigate any potential risks that these variants may have on our assay performance, we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID from September 1st to October 17th, 2022.
Our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariants, including B.1.1.529 BA.1, BA.2, BA.4, and BA.5 along with the new Omicron subvariants stated below:
． XBB - a hybrid of two BA.2 variants
． BQ.1.1 and BF.7 - the BA.5 subvariants
Meanwhile, we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following previously circulating Variants of Concern (VOCs):
． Alpha variant - known as B.1.1.7
． Beta variant - known as B.1.351
． Gamma variant - known as P.1
． Delta variant - known as B.1.617.2
*The SARS-CoV-2 RNA detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
． VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.